To evaluate the characteristics of patients with various substance-related disorders, and to examine rates of retention in treatment.
Methods:
We assessed the demographic characteristics, substance abuse, and psychological distress of 239 men and women at admission. Six-month performance was evaluated, using as criteria length of stay in treatment, abstinence, attendance in therapy sessions, and completion status at discharge.
Results:
Moderate to severe psychological distress was observed among these individuals. Higher levels of depression were found among women and in individuals with alcohol and sedative use disorders. The primary drug of abuse, frequency of use, and reason for entering treatment were the most significant predictors of retention.
Conclusions:
Opiate-addicted clients had the worst prognosis and treatment profiles. Further research is needed to identify factors that would optimize treatment for opiate dependence.
SimpsonDDSellsSB. Effectiveness of treatment for drug abuse: An overview of the DARP research program. Advances in Alcohol and Substance Abuse1982;2:7–29.
2.
HubbardRLMarsdenMERachalJVHarwoodHJCavanaughERGinzburgHM. Drug abuse treatment: A national study of effectiveness. Chapel Hill (NC): The University of North Carolina Press; 1989.
3.
HubbardRLCraddockSGFlynnPMAndersonJEtheridgeRM. Overview of 1-year follow-up in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behaviors1997;11:261–78.
4.
SimpsonDDBrownBS. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors1997;11:294–307.
5.
SimpsonDDJoeGWBroomeKMHillerMLKnightKRowan-SzalGA. Program diversity and treatment retention rates in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors1997;11:279–93.
6.
GottheilEMcLellanATDruleyKA. Length of stay, patient severity and treatment outcome: Sample data from the field of alcoholism. J Stud Alcohol1992;53:69–75.
7.
HoffmannNGMillerNS. Perspectives of effective treatment for alcohol and drug disorders. Psychiatr Clin North Am1993;16:127–40.
8.
McLellanATWoodyGEMetzgerDSMcKayJDurellJ, Alterman AI, and others. Evaluating the effectiveness of addiction treatments: Reasonable expectations, appropriate comparisons. Milbank Q1996;74:51–85.
9.
StarkMJ. Dropping out of substance abuse treatment: A clinically oriented review. Clinical Psychology Review1992;12:93–116.
10.
AgostiVNunesEStewartJWQuitkinFM. Patient factors related to early attrition from an outpatient cocaine research clinic: A preliminary report. International Journal on Addictions1991;26:327–34.
11.
GaineyRRWellsEAHawkinsJDCatalanoRF. Predicting treatment retention among cocaine users. International Journal on Addictions1993;28:487–505.
12.
McLellanATAltermanAIMetzgerDSGrissomGRWoodyGE, Luborsky L, and others. Similarity of outcome predictors across opiate, cocaine and alcohol treatments: Role of treatment services. J Consult Clin Psychol1994;62:1141–58.
13.
BrewerDDCatalanoRFHaggertyKGaineyRRFlemingCB. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction1998;93:73–92.
14.
MillerNSNinonuevoFGKlamenDLHoffmannNGSmithDE. Integration of treatment and posttreatment variables in predicting results of abstinence-based outpatient treatment after one year. J Psychoactive Drugs1997;29:239–48.
15.
AltermanAIMcLellanATShifmanRB. Do substance abuse patients with more psychopathology receive more treatment?J Nerv Ment Dis1993;181:576–82.
16.
RounsavilleBJKostenTRWeissmanMMKleberHD. Prognostic significance of psychiatric disorders in treated opiate addicts. Arch Gen Psychiatry1986;43:739–45.
17.
CharneyDAParaherakisAMNegreteJCGillKJ. The impact of depression on the outcome of addictions treatment. J Subst Abuse Treat1997;15:123–30.
18.
BeckATSteerRA. Beck Depression Inventory. New York: Harcourt Brace; 1987.
19.
DerogatisLR. The SCL-90-R: Administration, scoring and procedures manual II. Towson (MD): Clinical Psychometric Research; 1983.
20.
Canadian Centre on Substance Abuse. HIV/AIDS and injection drug use: A national action plan. Ottawa: Canadian Centre on Substance Abuse; 1997.
21.
GillKNolimalDCrowleyT. Antisocial personality disorder, HIV risk behavior and retention in methadone maintenance therapy. Drug Alcohol Depend1992;30:247–52.
22.
Des JarlaisDFriedmanSStoneburnerR. HIV infection and intravenous drug use: Critical issues in transmission dynamics, infection outcomes, and prevention. Review of Infectious Diseases1988;10:151–7.
23.
HubbardRLMarsdenMECavanaughERachalJVGinzburgHM. Role of drug-abuse treatment in limiting the spread of AIDS. Review of Infectious Diseases1988;10:377–83.
24.
LaqueilleXBayleFJSpadoneCJalfreVLooH. Treatment of depressive syndromes in detoxified drug addicts: Use of methadone. Biomed Pharmacother1996;50:279–82.
25.
ZwebenJE. Methadone maintenance in the treatment of opioid dependence: A current perspectiveWest J Med1990;152:588–99.
